Taisho Pharmaceutical R&D

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Taisho Pharmaceutical R&D sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 7 completed early-phase tilt upper quartile by trial count

Taisho Pharmaceutical R&D: 8 sponsored US clinical trials, none currently recruiting.

Taisho Pharmaceutical R&D sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 1 trials.

Upper-quartile sponsor footprint

Taisho Pharmaceutical R&D sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

COMPLETED Phase 1

A Single Ascending and Repeated Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TS-142 in Healthy Participants

NCT04464239
COMPLETED Phase 1

First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants

NCT03919409
TERMINATED Phase 2

A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder

NCT03093025
COMPLETED Phase 1

Effects of TS-134 on Ketamine-induced BOLD Signals in Healthy Subjects

NCT03141658
COMPLETED Phase 1

Safety, Tolerability and Pharmacokinetics of 14-day Multiple Dose Titrations of TS-134 in Healthy Volunteers

NCT03742791
COMPLETED Phase 1

Safety, Tolerability and Pharmacokinetics of Single Doses of TS-134 in Healthy Volunteers

NCT03746067
COMPLETED Phase 1

Exploratory Study Using Positron Emission Tomography With TS-121 and [11C]TASP0410699 in Healthy Adult Male Subjects

NCT02448212
COMPLETED Phase 2

Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)

NCT00914186

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 2

Therapeutic Areas

Healthy 1

How the Taisho Pharmaceutical R&D early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 7 completed (88%).

Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Healthy (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Taisho Pharmaceutical R&D: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Taisho Pharmaceutical R&D sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Taisho Pharmaceutical R&DAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Taisho Pharmaceutical R&D sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Taisho Pharmaceutical R&D sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Taisho Pharmaceutical R&D page

8 registered trials is a research-attention snapshot, not an endorsement of Taisho Pharmaceutical R&D or any single study.

  • None of Taisho Pharmaceutical R&D's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Healthy is the condition Taisho Pharmaceutical R&D studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Taisho Pharmaceutical R&D pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.